⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27628536 | 0.78 | — | — | |
| SCHEMBL29583143 | 0.78 | — | — | |
| SCHEMBL7314100 | 0.78 | — | — | |
| SCHEMBL601439 | 0.78 | — | — | |
| SCHEMBL27983614 | 0.78 | — | — | |
| SCHEMBL23982411 | 0.78 | — | — | |
| SCHEMBL3220945 | 0.78 | CHRNB2 (0.56) | — | |
| SCHEMBL3220953 | 0.78 | — | — | |
| SCHEMBL434891 | 0.78 | — | — | |
| SCHEMBL28006536 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8557978-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120214967-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| EP-1507796-B1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE INC (US) | 2012-05-02 | — | — | EP | disclosed |
| US-8084417-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8044195-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100197569-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7728127-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7713931-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7655621-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-6974797-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050239691-A1 | Cross-linked glycopeptide - cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2005-10-27 | — | — | US | disclosed |
| US-20050209132-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2005-09-22 | — | — | US | disclosed |
| US-6878686-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| EP-1507796-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | Theravance, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| EP-1434779-A2 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | Theravance, Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040033939-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2004-02-19 | — | — | US | disclosed |
| WO-2003099858-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030130173-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2003-07-10 | — | — | US | disclosed |
| WO-2003031449-A2 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2003-04-17 | — | — | WO | disclosed |